Glyceryl monolaurate (GML), also known as monolaurin, is a naturally occurring monoglyceride that has demonstrated notable antimicrobial properties, including activity against Staphylococcus aureus in laboratory and animal studies. Scientific investigations, primarily in vitro (test tube) studies, have shown that GML can inhibit the growth of various Gram-positive bacteria, including pathogenic staphylococci such as S. aureus and methicillin-resistant S. aureus (MRSA). Its mechanism of action is thought to involve disruption of bacterial cell membranes and interference with bacterial signaling pathways that contribute to virulence and biofilm formation.

Several peer-reviewed studies (e.g., Schlievert et al., 1992; 2019) support the antimicrobial activity of GML against staphylococci. Some animal studies have also demonstrated reduced colonization and infection severity when GML is applied topically or administered orally. However, robust, well-controlled clinical trials in humans are lacking, and the majority of evidence is preclinical. There is no widespread tradition of GML use for staph infections, and its use is primarily supported by recent scientific exploration.

In summary, while there is scientific rationale and preclinical evidence supporting the potential of glyceryl monolaurate in managing staph infections, especially as an adjunct or preventive agent, clinical efficacy and safety in humans remain to be conclusively established.